UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2286-5
Program Prior Authorization/Medical Necessity
Medication Vtama® (tapinarof)
P&T Approval Date 9/2022, 11/2022, 11/2023, 12/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Vtama cream is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque
psoriasis in adults and the topical treatment of atopic dermatitis in adults and pediatric patients 2
years of age and older.1
2. Coverage Criteriaa:
A. Plaque Psoriasis
1. Initial Authorization
a. Vtama will be approved based on all of the following criteria:
(1) Diagnosis of plaque psoriasis
-AND-
(2) Minimum duration of a 4-week trial and failure, contraindication, or intolerance
to one of the following topical therapies2:
(a) Corticosteroids (e.g., betamethasone, clobetasol, desonide)
(b) Vitamin D analogs (e.g., calcitriol, calcipotriene)
(c) Tazarotene
(d) Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
(e) Anthralin
(f) Coal tar
-AND-
(3) Patient is not receiving Vtama in combination with a Targeted Immunomodulator
[e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia
(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab), Tremfya
(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab),
Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
2. Reauthorization
© 2025 UnitedHealthcare Services, Inc.
1
a. Vtama will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to therapy
-AND-
(2) Patient is not receiving Vtama in combination with a Targeted Immunomodulator
[e.g., Enbrel (etanercept), Cimzia (certolizumab), Simponi (golimumab), Orencia
(abatacept), adalimumab, Stelara (ustekinumab), Skyrizi (risankizumab), Tremfya
(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Siliq (brodalumab),
Ilumya (tildrakizumab), Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq
(upadacitinib), Otezla (apremilast)]
Authorization will be issued for 12 months.
B. Atopic Dermatitis
1. Initial Authorization
a. Vtama will be approved based on all of the following criteria:
(1) Diagnosis of atopic dermatitis
-AND-
(2) History of failure, contraindication, or intolerance to one of the following
therapeutic classes of topical therapies:
(a) One of the following:
For mild atopic dermatitis: a topical corticosteroid [e.g., DesOwen
o
(desonide), hydrocortisone] (any potency)
For moderate atopic dermatitis: a topical corticosteroid of at least a
o
medium- to high-potency (e.g., Elocon (mometasone furoate),
Synalar (fluocinolone acetonide), Lidex (fluocinonide)]
(b) One topical calcineurin inhibitor [e.g., Elidel (pimecrolimus), Protopic
(tacrolimus)]*
-AND-
(3) Patient is not receiving Vtama in combination with a targeted immunomodulator
[e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib), Dupixent (dupilumab),
Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Vtama will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to therapy
© 2025 UnitedHealthcare Services, Inc.
2
-AND-
(2) Patient is not receiving Vtama in combination with a targeted immunomodulator
[e.g., Adbry (tralokinumab-ldrm), Cibinqo (abrocitinib), Dupixent (dupilumab),
Rinvoq (upadacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
* Elidel and Protopic/tacrolimus ointment require prior authorization.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim
logic. Use of automated approval and re-approval processes varies by program and/or
therapeutic class.
• Supply limits may be in place.
4. References:
1. Vtama [package insert]. Long Beach, CA: Dermavant Sciences Inc.; December 2024.
2. Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the
management and treatment of psoriasis with topical therapy and alternative medicine
modalities for psoriasis severity measures. J Am Acad Dermatol 2021;84:432-70.
Program Prior Authorization/Medical Necessity - Vtama® (tapinarof)
Change Control
9/2022 New program.
11/2022 Revised trial and failure requirement from either two topical therapies
or calcipotriene and betamethasone dipropionate to a trial and failure of
one topical therapy.
11/2023 Annual review. Updated not to be used in combination to Targeted
Immunomodulators. Simplified reauthorization criteria to only require
positive clinical response and not used in combination with other
treatment medications.
12/2024 Annual review. Removed prescriber requirement. Updated initial
authorization to 12 months.
5/2025 Added coverage criteria for atopic dermatitis. Updated background and
reference.
© 2025 UnitedHealthcare Services, Inc.
3